23andMe will keep offering customers its DNA testing services after being bought out of bankruptcy. New York-based biotech company Regeneron Pharmaceuticals announced an agreement on Monday to purchase the 23andMe startup for $256 million, alongside its Total Health and Research Services business and biobank of customer data and genetic samples. Regeneron is the winner of […]